Marinomed Biotech Future Growth
Future criteria checks 5/6
Marinomed Biotech is forecast to grow earnings and revenue by 57.3% and 40.8% per annum respectively while EPS is expected to grow by 57.3% per annum.
Key information
57.3%
Earnings growth rate
57.3%
EPS growth rate
| Pharmaceuticals earnings growth | 14.0% |
| Revenue growth rate | 40.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 17 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 30 | 3 | 11 | 8 | 1 |
| 12/31/2025 | 23 | 2 | 14 | 5 | 1 |
| 12/31/2024 | 18 | 0 | 8 | 2 | 1 |
| 12/31/2023 | 9 | -7 | -5 | -5 | N/A |
| 9/30/2023 | 11 | -6 | -6 | -6 | N/A |
| 6/30/2023 | 12 | -6 | -5 | -5 | N/A |
| 3/31/2023 | 12 | -7 | -5 | -5 | N/A |
| 12/31/2022 | 11 | -6 | -5 | -5 | N/A |
| 9/30/2022 | 13 | -5 | -5 | -4 | N/A |
| 6/30/2022 | 13 | -5 | -2 | -2 | N/A |
| 3/31/2022 | 12 | -6 | -3 | -2 | N/A |
| 12/31/2021 | 12 | -6 | -6 | -5 | N/A |
| 9/30/2021 | 9 | -8 | -11 | -7 | N/A |
| 6/30/2021 | 9 | -7 | -12 | -9 | N/A |
| 3/31/2021 | 9 | -7 | -13 | -9 | N/A |
| 12/31/2020 | 8 | -6 | -11 | -7 | N/A |
| 9/30/2020 | 8 | -6 | -8 | -6 | N/A |
| 6/30/2020 | 7 | -6 | -9 | -5 | N/A |
| 3/31/2020 | 7 | -6 | -8 | -6 | N/A |
| 12/31/2019 | 7 | -7 | -10 | -8 | N/A |
| 9/30/2019 | 5 | -14 | -8 | -8 | N/A |
| 6/30/2019 | 5 | -15 | -9 | -9 | N/A |
| 3/31/2019 | 5 | -14 | -7 | -7 | N/A |
| 12/31/2018 | 5 | -12 | -5 | -4 | N/A |
| 9/30/2018 | 6 | -4 | -4 | -4 | N/A |
| 12/31/2017 | 5 | -2 | -2 | -2 | N/A |
| 12/31/2016 | 4 | -2 | N/A | -3 | N/A |
| 12/31/2015 | 3 | -1 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MARI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.1%).
Earnings vs Market: MARI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MARI is expected to become profitable in the next 3 years.
Revenue vs Market: MARI's revenue (40.8% per year) is forecast to grow faster than the Austrian market (-2.2% per year).
High Growth Revenue: MARI's revenue (40.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MARI's Return on Equity is forecast to be high in 3 years time